Neuberger Berman Group’s BridgeBio Pharma BBIO Stock Holding History

Neuberger Berman Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.1M	Buy	552,158 +335,843	+155%	+$23.5M	0.03%	552
2026 Q1	$16.1M	Sell	216,315 -4,930	-2%	-$357K	0.01%	709
2025 Q4	$16.9M	Buy	221,245 +2,549	+1%	+$167K	0.01%	688
2025 Q3	$11.4M	Buy	218,696 +38,407	+21%	+$1.87M	0.01%	775
2025 Q2	$7.78M	Buy	180,289 +41,990	+30%	+$1.53M	0.01%	849
2025 Q1	$4.78M	Buy	+138,299	New	+$4.66M	﹤0.01%	943
2021 Q3	–	Sell	-4,183	Closed	-$250K	–	1766
2021 Q2	$250K	Buy	+4,183	New	+$239K	﹤0.01%	1661
2021 Q1	–	Sell	-4,083	Closed	-$284K	–	1764
2020 Q4	$284K	Buy	+4,083	New	+$197K	﹤0.01%	1530
2020 Q1	–	Sell	-6,500	Closed	-$228K	–	1529
2019 Q4	$228K	Buy	+6,500	New	+$180K	﹤0.01%	1447

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Neuberger Berman Group's BBIO Position: Q2 2026 in Review

Neuberger Berman Group increased its BridgeBio Pharma (BBIO) stake by 155% in Q2 2026, buying an estimated $23.5M and bringing the position to 552,158 shares worth $41.1M. The position accounts for 0.03% of the portfolio, ranked #552.

Neuberger Berman Group first reported a position in BBIO in Q4 2019 and has held it in 9 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Neuberger Berman Group held 552,158 shares of BridgeBio Pharma worth $41.1M as of Q2 2026.
Neuberger Berman Group bought 335,843 BridgeBio Pharma shares in Q2 2026, an estimated $23.5M.
BridgeBio Pharma made up 0.03% of Neuberger Berman Group's portfolio in Q2 2026, its #552 holding.
Neuberger Berman Group first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 9 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.